BECOME A MEMBER

Get my best investment ideas sourced from stocks with liquid trading

There is more to Undervalued-Shares.com than my free Weekly Dispatches.

Join my global audience (Members from over 80 countries!) with a choice of two Memberships:

Annual Membership

For just USD 49/year, you'll get:

Z

10 extensive research reports (PDF format) each year; see my FREE sample report (4MB)

Z

Archive with all 50+ past research reports

Z

Updates on previous research reports 

Z

Email alerts for reports and updates

That's just USD 4 per month to empower you to run your own portfolio.

Lifetime Membership

For USD 999 (one-off), you'll enjoy all the benefits of Annual Members, plus:

Z

4 additional investment opportunities each year, sourced from small- and mid-caps (i.e., less liquid markets)

Z

Priority booking of reader events and trips

These privileges for Lifetime Members will evolve and expand as the website grows.

Any unused fees from an existing Annual Membership will automatically be deducted.

What members say

|

Your work rate is simply outstanding! I also admire your ability to put your politics aside and invest as you see it.

Guy D., Australia

|

Swen Lorenz is offering one of the world's cheapest investor clubs. For just $50 per year (or €4 per month), you get more value than from any investor magazine. There are certainly other specialised investment newsletters that are similarly fascinating and successful, but these usually cost 10-20 times more!

Andreas Lambrou, emerging market specialist and publisher, Germany

|

This Membership is the best investment in your own stock market future. Anyone looking for an experienced opportunity finder will find what they need with Swen Lorenz!

Moritz H., Germany

|

I count Swen up there with Jim Rogers and Doug Casey & The Wandering Investor as inspirations for my global investing career.

Marvin L., USA

|

Gotta say that @uv_shares is one of my favorite blogs. We are paid up subscribers. Always some quirky stock I haven’t heard of. Recommend you follow…

Kuppy, AdventuresInCapitalism

|

I just wanted to praise you for the work you are presenting us and for the way your write your reports (clean, understandable, easy to consume, and focused on long term value - and not short term propaganda).

Tiago M., Portugal

|

I am a Lifetime subscriber to your newsletter. It is one of the best, if not the best out there in this space.

Hung-Wah C., Hong Kong

|

You are the Sherlock Holmes of the stock market. Love your analysis. It's not only pretty accurate but fun to read.

Pablo, Argentina

|

Your unique, nonconformist approach to investing and life is second to none and those who are following you are always benefiting on multiple levels. Who would have thought that there are still huge treasure chests waiting to be dug out, not with the shovels and pickaxes of the past but with curiosity, wisdom, persistence and diligence?

Andreas S., Austria

NOT SURE YET?

Check out a
FREE sample report

Subscribe to the free Weekly Dispatches

Email me if you have questions

My commitment to you



No aggressive affiliate marketing, no advertisement for other services, no flood of spam emails.

Z

Liquid, world-class companies that anyone can buy into (and the occasional small cap special situation or alternative investment).

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.